Myelodysplastic syndromes classification and risk stratification.
Myelodysplastic syndromes (MDS) are spectrum of bone marrow failure disorders that share a common pathologic feature: cytologic dysplasia. The classification of MDS reflects the understanding of the disease. It is hoped that in the future classification and risk stratification will be based on underlying pathobiology of different disease subsets and molecular signatures where the pathologic classification represents their phenotype. This article reviews MDS classification and risk stratification highlighting differences between the various systems.
Komrokji
Rami S
RS
H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. rami.komrokji@moffitt.org
Zhang
Ling
L
Bennett
John M
JM
D001853:Bone Marrow / Q000473:pathology; D019070:Cell Lineage; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000648:ultrastructure; D006801:Humans; D008962:Models, Theoretical; D009190:Myelodysplastic Syndromes / Q000145:classification* / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000473:pathology; D054547:National Cancer Institute (U.S.); D010641:Phenotype; D011379:Prognosis; D012042:Registries; D018570:Risk Assessment; D012720:Severity of Illness Index; D012955:Societies, Medical; D014481:United States; D014944:World Health Organization